glp-1 obesity drug news today sep 30 2025 september GLP-1 Drugs: 2025 Pulse Survey (U.S.) Lilly launches GLP-1 pill, kicking

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 diabetes patients.

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

However, no significant improvements were observed in LVEF, LVEDV, LVESV, or GLS

Keep out of reach of children under 18